Synthesis and evaluation of the antiproliferative efficacy of BRM270 phytocomposite nanoparticles against human hepatoma cancer cell lines.
Antineoplastic Agents, Phytogenic
/ chemical synthesis
Apoptosis
/ drug effects
Carcinoma, Hepatocellular
/ drug therapy
Cell Proliferation
/ drug effects
Chromatography, High Pressure Liquid
Cluster Analysis
Drug Delivery Systems
/ methods
Drug Liberation
Drugs, Chinese Herbal
/ chemical synthesis
Gene Expression Regulation, Neoplastic
/ drug effects
Hep G2 Cells
Humans
Liver Neoplasms
/ drug therapy
Microscopy, Electron, Scanning
Nanoparticles
/ chemistry
Reproducibility of Results
Anticancer activity
BRM270 nanoparticles
Human hepatoma cancer cells
Mechanical-milling method
Phyto-composite
Journal
Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
03
05
2018
revised:
17
10
2018
accepted:
27
11
2018
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
18
6
2019
Statut:
ppublish
Résumé
BRM270 is the most leading phytochemical extract that possesses potent anticancer properties. A major challenge associated with this drug is its low bioavailability and thus requires high dosages for cancer treatment. Here, we report the novel nano-synthesis of phyto-composite, BRM270 for the first time by mechanical milling method with specific modifications for enhanced cytotoxicity against HepG2 human hepatoma cancer cells. Unlike free BRM270 and other phytomedicines, BRM270 nanoparticles (BRM270 NPs) are well-dispersed and small sized (23 to 70 nm) which is believed to greatly enhanced cellular uptake. Furthermore, the acidic tumor microenvironment attracts BRM270 NPs enhancing targeted therapy while leaving normal cells less affected. The comparative cytotoxicity analysis using MTT assay among the three treatment groups, such as free BRM270, BRM270 NPs, and doxorubicin demonstrated that BRM270 NPs induced greater cytotoxicity against HepG2 cells with an effective drug concentration of 12 μg/ml. From FACS analysis, we observed an apoptotic cell death of 44.4% at BRM270 NPs treated cells while only 12.5% found in the free BRM270 treated cells. Further, the comparative relative expression profiling of the candidate genes were showed significant (p < 0.05) down-regulation of IL6, BCL2, p53, and MMP9 in the BRM270 NPs treated cells, compared to the free BRM270 and doxorubicin. Indeed, the genes, CASPASE 9 and BAX have shown significant (p < 0.05) upregulation in cells treated with BRM270 NPs as compared to counter treatment groups. The investigation of the signal pathways and protein-protein network associations were also carried out to elucidate the functional insights underlying anti-cancer potential of BRM270 NPs in HepG2 cells. Taken together, our findings demonstrated that these uniquely engineered BRM270 NPs effectively enter into the cancer cells due to its acidic microenvironment thereby inducing apoptosis and regulate the cell-proliferation in-vitro at extremely low dosages.
Identifiants
pubmed: 30678901
pii: S0928-4931(18)31253-0
doi: 10.1016/j.msec.2018.11.055
pii:
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Drugs, Chinese Herbal
0
Jiedu Xiaozheng Yin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
166-176Informations de copyright
Copyright © 2018. Published by Elsevier B.V.